Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
Energex System's Experimental Non-Pharmacological Treatment Exceeds Expectations in Reducing Liver Inflammation in Refractory Hepatitis C Patients
July 9th, 2007
Energex Systems, Inc. announced that its experimental therapy known as HemoModulation was effective in reducing viral load and liver inflammation in non-responding Hepatitis C patients. The trial was conducted under an Investigational Device Exemption (IDE) that was granted by the Federal Food and Drug Administration (FDA) in February 2006. Hepatitis C (HCV) is a viral infection of the liver and a major cause of chronic liver disease, including cirrhosis and liver cancer, and is now recognized as the leading cause of liver transplantation in the United States. HCV is spread primarily by direct contact with human blood. The World Health Organization estimates that about...
Source: Hepatitis Weekly (2007-07-09)
|
